"US Breast Cancer Drug Market, Drug Price, Dosage and Clinical Trials Insight 2026" Report Highlights:
US Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026
US Breast Cancer clinical Trials: 350 Drugs in Pipeline
More Than 130 Drugs in Phase II and Higher Phases of Trials
Detailed Clinical Insight on 350 Drugs In Pipeline and 62 Drugs Available in Market
Marketed Breast Cancer Drugs Dosage, Patent and Pricing
Drugs Classification by Class: SERD, EGFR, Mitotic Inhibitors, CDK 4/6, Hormonal, PARP Inhibitors and More
Insight on Ongoing Research and Collaborations
900 Page In-Depth Analysis on Clinical and Commercial Indicators
Breast cancer therapeutics market in the US represents itself as a paralleled contributor to the total pharmaceutical market in the country. The high mean value of the market is oftenly observed as of high interest by the researchers in the emerged market. The upside potential of the market is booming, with only very little down quirks. In addition to this, the country’s outlook of the breast cancer drug use and spending for research and development is a must-watched parameter for the other emerging markets of the world. The research report developed for the market includes all the latest predictions for the US breast cancer market, in addition to this including several areas of growth, research and development process and many more. The report involves the impact of the novel drug launches on the already available drugs as well as the driving forces for the available medicines. In addition to the comprehensive outlook for the massive number of drugs available for the treatment of breast cancer in the country, the research report also highlights the impact of the available breast cancer drugs on the other pharmaceutical markets available.
For the US breast cancer therapeutics market, it is concluded that the market growth rate is expected to increase at a double digit of more than 10% CAGR rate over the next few years. The total invoice spending for the research and development process of different breast cancer drugs is driving certain factors such as novel product uptake and the pricing of the drug. In the US, the pipeline for research and development are growing towards success at historic level, thus resulting in the generation of a phase that will lead to novel product launches in the upcoming years. It is concluded for the US breast cancer market that the speedy growth of the market is dependent on the increased volumes and quality of the data analytics that is driving the market towards several speedy drug approvals for different stages of breast cancer.
The country for boosting the overall efficacy of the market with respect to providing healthcare benefits to millions of patients, is going to use fast-track and breakthrough designations. By delivering continuous efforts, the transparent market for breast cancer in the country is going to deliver more impactful efforts to address the need of the patients who are not able to respond to the available therapies, thus inclining the market towards causing an emergence of personalized medicine in the breast cancer treatment.
As per "US Breast Cancer Drug Market, Drug Price, Dosage and Clinical Trials Insight 2026" report findings, it can be observed that research and development productivity, strong clinical background, efficient clinical pipeline and many more are the prominent keys to growth and success of the market in the past few years. Severe reduction in the cost of developing drugs and therapies due to the arrival of innovative clinical technologies such as artificial intelligence has made the market promising enough to sustain in the globe as a prominent leader. In addition to it, the increase in the number of novel drug applications and approvals by the US FDA also illustrates the increase in the market capacity towards ending the demand of the patients. The US breast cancer therapeutics market can be witnessed to have several growing trends that is driving the market towards making the path for more blockbuster drugs and tools in the future.
Figure 15-1: Herceptin – Approval Year by Cancer Type
Figure 15-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2021
Figure 15-3: Herceptin – Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2021
Figure 15-4: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$), January’2021
Figure 15-5: Herceptin – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), January’2021
Figure 15-6: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), January’2021
Figure 15-7: US - Herceptin Annual Sales Value (US$/CHF Million), 2017 - 2019
Figure 15-8: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2019
Figure 15-9: US - Herceptin Quarterly Sales Value (US$ Billion), Q1-Q3, 2020
Figure 15-10: Avastin – Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$), January’2021
Figure 15-11: Avastin – Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$), January’2021
Figure 15-12: Avastin’s Biosimilar - FDA Approval Year
Figure 15-13: Mvasi - Price for 4ml Supply and Price per ml of Intravenous Solution (US$), January’2021
Figure 15-14: Mvasi - Price for 16 ml Supply and Price per Unit of Intravenous Solution (US$), January’2021
Figure 15-15: Zirabev - Price for 4ml Supply and Price per unit of Intravenous Solution (US$), January’2021
Figure 15-16: Zirabev - Price for 16 ml Supply and Price per unit of Intravenous Solution (US$), January’2021
Figure 15-17: US - Avastin Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 15-18: US - Avastin Quarterly Sales Value (US$ Billion), 2019
Figure 15-19: US - Avastin Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 15-20: Perjeta - Approval Year by Cancer Type
Figure 15-21: Perjeta – Patent Expiration Year by Region
Figure 15-22: Perjeta – Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January’2021
Figure 15-23: Perjeta – Initial and Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), January’2021
Figure 15-24: Perjeta – Minimum and Maximum Treatment Cost for Breast Cancer (US$), January’2021
Figure 15-25: Perjeta – Minimum and Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January’2021
Figure 15-26: US - Perjeta Annual Sales Value (US$/CHF Million), 2017 - 2019
Figure 15-27: US - Perjeta Quarterly Sales Value (US$ Billion), 2019
Figure 15-28: US - Perjeta Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 15-29: Kadcyla – FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer
Figure 15-30; Kadcyla – Price for Single Unit of 100mg and 160mg Intravenous Powder for Injection (US$), January’2021
Figure 15-31: Kadcyla - Duration of Single Treatment Cycle and Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
Figure 15-32: Kadcyla – Average Cost of Single Treatment Cycle and Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January’2021
Figure 15-33: Kadcyla – Recommended Dose After 1st and 2nd Dose Reduction (mg/m2)
Figure 15-34: US - Kadcyla Annual Sales Value (US$/CHF Million), 2017 - 2019
Figure 15-35: US - Kadcyla Quarterly Sales Value (US$ Billion), 2019
Figure 15-36: US - Kadcyla Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 15-37: Tecentriq - Price for 14ml Supply and Price per ml of 840mg/14ml Intravenous Injection (US$), January’2021
Figure 15-38: Tecentriq - Price for 20ml Supply and Price per ml of 1200mg/20ml Intravenous Injection (US$), January’2021
Figure 15-39: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January’2021
Figure 15-40: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January’2021
Figure 15-41: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January’2021
Figure 15-42: US - Tecentriq Annual Sales Value (US$/CHF Million), 2017 - 2019
Figure 15-43: US - Tecentriq Quarterly Sales Value (US$ Billion), 2019
Figure 15-44: US - Tecentriq Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 15-45: Keytruda – Patent Expiration Year by Region
Figure 15-46: Keytruda – Price for 4ml and 8ml Supply and Price per ml of Intravenous Injection (US$), January’2021
Figure 15-47: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), January’2021
Figure 15-48: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2021
Figure 15-49: US - Keytruda Annual Sales Value (US$ Billion), 2017 - 2019
Figure 15-50: US - Keytruda Quarterly Sales Value (US$ Million), 2018 and 2019
Figure 15-51: US - Keytruda Quarterly Sales Value (US$ Million), 2020
Figure 15-52: Enhertu – Cost of Single Supply and Single Treatment Cycle (US$), January’2021
